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Abstract 
Aim: To evaluate the reported use of Data Monitoring Committees (DMCs), the frequency of 
interim analysis, pre-specified stopping rules and early trial termination in neonatal randomised 
controlled trials (RCTs). 
Methods: We reviewed neonatal RCTs published in four high impact general medical journals, 
specifically looking at safety issues including documented involvement of a DMC, stated interim 
analysis, stopping rules and early trial termination. We searched all journal issues over an 11-
year period (2003-2013) and recorded predefined parameters on each item for RCTs meeting 
inclusion criteria.  
Results: Seventy neonatal trials were identified in four general medical journals: Lancet, New 
England Journal of Medicine (NEJM), British Medical Journal and Journal of American Medical 
Association (JAMA).  43 (61.4%) studies reported the presence of a DMC, 36 (51.4%) explicitly 
mentioned interim analysis; stopping rules were reported in 15 (21.4%) RCTs and 7 (10%) trials 
were terminated early. The NEJM most frequently reported these parameters compared to the 
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other three journals reviewed. 
Conclusion: While the majority of neonatal RCTs report on DMC involvement and interim 
analysis there is still scope for improvement. Clear documentation of safety related issues 
should be a central component of reporting in neonatal trials involving newborn infants.  
 
Key Notes: 
• Data Monitoring Committees are an important safety aspect of RCTs, particularly in trials 
involving vulnerable populations.  
• While the majority of RCTs included in this review reported on DMC involvement, our 
results highlight deficiencies in the reporting of neonatal RCTs.  
• Clear documentation of safety related issues should be a central component of reporting 
in neonatal trials involving newborn infants.  
 
Key words  
Clinical trials, randomised controlled trials, RCTs, data monitoring committees, DMCs, stopping 
rules, interim analysis, neonatal 
 
Introduction 
Neonatal randomised controlled trials (RCTs) recruit a vulnerable group of patients, the 
protection of whom is of critical importance. The balance between risks and benefits is a central 
ethical issue in research involving children and the complexity of risk determination is 
highlighted by the recent SUPPORT (Surfactant, Positive Pressure, and Oxygenation 
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Randomized Trial ) controversy. (1-4) Infants cannot consent to research so it is left to others, 
parents, researchers and regulators, to decide if the risk-benefit ratio is acceptable and that 
sufficient clinical equipoise exists to justify conduct of an RCT. (5) The complexities of 
conducting comparative research trials such as SUPPORT are highlighted in a recent editorial 
from the Hastings Centre.(6) 
Patient safety is critical to the conduct of RCTs. One method of ensuring patient safety is the 
establishment of a Data Monitoring Committee (DMC). This consists of a group of external 
experts whose main function is to safeguard the interests of the study participants. This is 
achieved through vigilance over the conduct of the trial, performing analysis of safety data and 
predetermined interim analysis of the efficacy endpoint(s).(7-9) A DMC must consider both 
individual and collective factors when making recommendations regarding the appropriateness 
of trial continuation and, if necessary, obtain unpublished and interim data from sources outside 
of the trial.(4, 8) The recommendations of a DMC will affect the credibility of the trial, the validity 
of its results, and indirectly, their implementation in clinical practice.(9) For example, evidence 
suggests that treatment effects of interventions in trials that are stopped early for benefit are 
systematically overestimated.(10, 11)  
In order to properly assess the recommendations of a DMC, their activities and considerations 
must be adequately reported.(9) Deficiencies in the reporting of pediatric RCTs were highlighted 
in a recent systematic review which found that only 17% of trials published in high-impact 
journals reported on DMCs, interim analysis or early termination.(9) Published guidelines are 
available for the appointment and operational procedures of DMCs.(12, 13) Guidance is also 
available regarding which types of trials require DMCs. In general, RCTs that address major 
health outcomes and are designed to address efficacy and safety issues should have a DMC 
(14) and it is appropriate establish the additional protection of a DMC in cases involving 
vulnerable populations. (14-16) 
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Neonates are one of the most vulnerable subgroups of the pediatric population and, to our 
knowledge, documented DMC involvement  in neonatal RCTs has not been previously 
published. We were interested in a number of issues pertaining to DMCs in neonatal RCTs. We 
wanted to determine the documented use of DMCs, the frequency of interim analysis 
performed, the presence of pre-specified stopping rules and early trial termination of neonatal 
clinical trials published in high-impact general medical journals. 
 
Methods: 
Eligibility criteria 
Neonatal trials published in four general medical journals (British Medical Journal (BMJ), 
Journal of the American Medical Association (JAMA), Lancet and The New England Journal of 
Medicine (NEJM)) during the years Jan 1 2003 to Dec 31 2013 were included. These journals 
have high impact factors and are known to publish clinical trials with the potential to significantly 
influence clinical practice. We included randomised controlled trials involving newborn infants 
investigating any therapeutic or preventive health care interventions in preterm infants or term 
infants younger than 28 days of life.  
 
Literature search 
All issues of each of the included journals listed above for the years 2003 to 2013 inclusive were 
searched by a single researcher (SG: NEJM; LP: JAMA, Lancet; IR; BMJ) to identify any 
neonatal RCT. Two independent reviewers (JM, ED) independently screened the full-text 
articles of included citations to confirm suitability for inclusion and where disagreements arose, 
these were resolved by consensus. The literature review was conducted over a 6-month period 
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between January and July 2014. We did not assess the overall quality of each manuscript, but 
specifically sought information pertaining to the mention of a DMC or Data Safety Monitoring 
Board (DSMB), whether interim analysis were performed, the presence of pre-specified 
stopping rules and early trial termination.  
 
Data Extraction and Analysis  
For each included article, two authors independently searched all sections of the manuscript for 
relevant information, including abstract and acknowledgements, and extracted data using a 
computerized data collection form (Microsoft Excel). Evidence-based parameters for data 
collection regarding DMC characteristics, interim analyses and clinical trial stopping rules were 
clearly defined.(12-14, 16) The following information was extracted: trial monitoring by a DMC, 
performance of interim analysis, pre-specified valid rules or guidelines for early trial termination 
(i.e. stopping rules), whether the study was terminated early, and if so why. The reported use of 
DMCs was estimated from the proportion of identified RCTs that explicitly mentioned the use of 
a DMC in the manuscript. Statistical analysis for this study was performed using IBM SPSS 
Statistics 22.0 (http://www.spss.com). The number of articles per journal was represented as a 
proportion of the overall number of RCTs published. Comparison between journals was 
erformed using chi square analysis. All tests were two-sided and a p-value <0.05 was 
considered to be statistically significant. 
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Results 
Our initial search identified a total of 3054 RCTs. The NEJM published 1107 RCTs, while the 
Lancet, JAMA and BMJ published 807, 588 and 552 RCTs respectively. Seventy (2.3%) of all 
the RCTs identified involved neonatal participants.  The Lancet published the highest proportion 
of neonatal RCTs relative to their total number of RCTs (3.5%) and contributed the most 
neonatal trials to this review (n= 28, 40%). The BMJ, JAMA and NEJM published similar 
proportions of neonatal RCTs, at 2.0% (n=11), 1.9% (n=11) and 1.8% (n=20) respectively.  
Data safety monitoring reporting by journal is displayed in table 1. Overall, 43 (61.4%) of the 
published clinical trials commented on the presence of a DMC, 36 articles (51.4%) explicitly 
mentioned interim analysis, and a total of seven (10%) neonatal trials were terminated early. 
There was a difference in the proportion of studies that documented the presence of a DMC.  
Ninety percent of the neonatal trials published in the NEJM reported on DMCs, compared to 
63.2% in JAMA, 46.4% in the Lancet and 45% in the BMJ (p-value of 0.013). Interim analyses 
were reported in just over half (51.4%) of all studies, again there was a significant difference 
between journals (p=0.018).  
Of the absolute number of planned interim analysis reported  (n=31), on 8 occasions one interim 
analysis was performed, on 13 occasions there were two planned interim analysis and there 
were greater than 2 on 6 occasions.  Stopping rules were reported in 21.4% of all studies, there 
was a significant difference between clinical trials published in the different  journals with regard 
to reporting stopping rules (p=0.18).  Again, the NEJM was the journal most likely to report 
stopping rules (45%). 
We identified a total of seven (10%) RCTs terminated early.  Four were terminated for benefit, 
two for harm and one RCT readjusted its sample size because the primary outcome was 
occurring at an increased frequency than estimated in the protocol. A DMC was documented  in 
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all RCTs terminated early. A stopping rule was not reported in the published manuscript in three 
of these seven trials terminated early 
 
Discussion 
The safe conduct of RCTs is paramount, especially when dealing with vulnerable population 
groups such as newborn infants. One critical component consists of local or national ethics 
committees review to ensure patients are not exposed to unnecessary risks. Studies that 
involve medications or medical devices are also reviewed by national agencies such as the 
MHRA (Medicines and Healthcare Products Regulatory Agency). Another important component 
of the safe conduct of a clinical trial is the presence of a Data Monitoring Committee (DMC). The 
decision to use a DMC is based on numerous factors, including amongst others the risk to 
subjects, the complexity of the trial design, and the number of clinical sites involved. (15, 17) 
Clinical and methodological criteria are available to decide if a DMC is required for a particular 
trial.(16) We believe reporting the presence or absence of a DMC and its functions is an 
important aspect of the conduct of the clinical trial.  
The development of original CONSORT statement was fueled by a lack of adequate reporting of 
RCTs(18). The CONSORT 2010 document explicitly states and recommends that authors report 
whether they or a DMC performed interim analyses, and if so, how many there were, what 
triggered them, the statistical methods used (including any formal stopping rule), and whether 
they were planned before the start of the trial.(18) Disappointingly, we found that only 61.4% of 
all RCTS published in these four journals reported on the involvement of a DMC, 51.4% 
explicitly mentioned interim analysis and only 21.4% reported a statistically valid stopping rule.  
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While the neonatal trials included in this review attained higher reporting standards compared to 
a similar review of pediatric trials(9), our results show heterogeneous practices and suboptimal 
reporting of these important safety concerns across the four journals.  Since DMCs have the 
power to both safeguard trial participants and influence the outcome by way of recommending 
termination or continuation of studies, we believe clear and transparent reporting of their 
involvement is essential. We chose 2003 onwards as our initial time point because the first 
publications relating to consolidated reporting of clinical trials occurred in 1996 and the revised 
statement was published in 2001. It is important to note that we were not applying standards 
from CONSORT 2010 to trials published before that point. It is also important to highlight that 
we are not assessing the quality of the individual trials we have we included in this review; we 
are assessing important aspects pertaining to patient safety reported in published manuscripts.  
The trials published in the NEJM demonstrated more comprehensive reporting of these 
parameters compared to the other included journals (table 1). It is unclear why this is the case. 
It is the role of investigators to include these important factors in the submitted manuscript, the 
role of reviewers to ensure that these critical safety issues are addressed and the role of the 
editorial staff to ensure these are included in the final published article. In this way physicians, 
allied healthcare professionals, patients, families and the general public can be reassured that 
trials conducted in these patient group recognize patient safety as the key aspect of these 
important studies.  
However, despite meticulous trial conduct and reporting, controversy can still engulf a newborn 
trial. The SUPPORT study(3), a large US trial investigating the optimal range of target oxygen 
saturations for extremely premature infants, raised ethical issues regarding how the risks of 
research compares to the risks of standard clinical practice. In 2011 the SUPPORT trials’ 
informed consent process was investigated by the Office for Human Research Protections 
(OHRP) of the U.S. Department of Health and Human Services. While the misgivings of the 
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OHRP were not shared by many in the neonatal community, it nonetheless generated 
apprehension regarding the conduct of clinical trials in this at risk group of patients.(2) Clinical 
research is crucial to the advancement of the medical science and maximizing safety features.  
One way of trying to alleviate concerns is ensuring complete and accurate reporting of RCTs in 
medical journals.  Enhancing the information in the public domain with more consistent reporting 
of primary trials, ensuring safety aspects are consistently reported in the primary publication 
could help restore any perceived lack of confidence in clinicians. Whilst we acknowledge that 
much of this information should be provided in various databases such as clinical trials.gov we 
believe this information should be prioritized and included either in the body of the manuscript or 
as an appendix to the manuscript, which is readily accessible to the journal reader.  
One of the main limitations of this study is that we identified trials from a restricted set of 
journals that have high-impact factors and are known to publish trials in a broad range of 
conditions and age categories. These studies may not be representative of the majority of 
neonatal trials. However, we chose high caliber medical journals with good quality studies so it 
is possible that the shortcomings we identified might in fact be more prevalent in neonatal trials 
published in other journals. We concentrated our efforts on the actual reported manuscript, and 
did not review various clinical trial websites as mentioned above. We did not contact journal 
editors to clarify their policy of this information in the published manuscript. Whilst the individual 
journals will have their own publication policies, the CONSORT Statement is endorsed by all 4 
journals reviewed.  
Where there is inconsistency in reporting clinical trials concerns can arise. Therefore, we call for 
clear reporting of DMC involvement or lack thereof in neonatal RCTs; submitted manuscripts 
should state the involvement of a DMC and  interim analyses and stopping rules should be 
reported in accordance with evidenced based guidelines.(12, 14, 18) This should avoid 
confusion and provide additional clarity regarding central safety components of clinical trials 
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involving newborn infants and may alleviate some of the concerns that may arise amongst 
healthcare workers, the general public, funding agencies and government agencies of clinical 
trials conducted in this group of patients. 
 
Conclusion   
DMCs represent an important safety aspect of RCTs. While the majority of neonatal RCTs 
included in this study report on DMC involvement and interim analysis there is still scope for 
improvement. Clear documentation of safety related issues should be a central component of 
reporting in neonatal trials involving newborn infants 
 
Abbreviations: DMC; data monitoring committee, RCT; randomized controlled trial, NEJM: 
New England Journal of Medicine, BMJ; British Medical Journal, JAMA; Journal of American 
Medical Association,  
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Table 1: Data safety monitoring reporting by journal 
  
Journal 
Neonatal RCTs    
 n (%) 
DMC reported  
n (%) 
Interim Analysis  
n (%) 
stopping rule reported  
n (%) 
Trial terminated early  
n (%) 
Lancet 28 (40.0) 13 (46.4) 12 (42.9) 3 (10.7) 3 (10.7) 
NEJM 20 (28.6) 18 (90.0) 16 (80.0) 9 (45) 4 (20.0) 
JAMA 11 (15.7) 7 (63.6) 5 (45.5) 1 (9.1) 0 
BMJ 11 (15.7) 5 (45.5) 3 (27.3) 2 (18.2) 0 
Total 70 (100) 43 (61.4) 36 (51.4) 15 (21.4) 7 (10.0) 
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